CTIC NASDAQ
CTI BioPharma Corp.
1W: +0.2%
1M: +1.1%
3M: +111.4%
1Y: +52.3%
3Y: +615.8%
5Y: +80.7%
$9.10
Last traded 2023-06-23 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.2B
52W Range4.01-9.1
Volume5,558,437
Avg Volume6,356,559
Beta0.83
Dividend—
Analyst Ratings
Company Info
CEOAdam R. Craig
Employees127
SectorHealthcare
IndustryBiotechnology
IPO Date1997-03-21
Websitectibiopharma.com
3101 Western Avenue
Seattle, WA 98121
US
Seattle, WA 98121
US
206 282 7100
About CTI BioPharma Corp.
CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key product is VONJO (pacritinib), an oral kinase inhibitor currently under investigation, specifically designed to target JAK2, FLT3, IRAK1, and CSF1R for the management of adult patients with myelofibrosis. The company holds licensing and collaboration agreements with Teva Pharmaceutical Industries Ltd., SBIO Pte Ltd., and Baxalta. Established in 1991 and based in Seattle, Washington, CTI BioPharma Corp. was previously known as Cell Therapeutics, Inc., adopting its current name in May 2014.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| BVF PARTNERS L P/IL | U-Tender | 43,139 | $9.10 | 2023-06-26 |
| BVF PARTNERS L P/IL | U-Tender | 12 | — | 2023-06-26 |
| BVF PARTNERS L P/IL | U-Tender | 17 | — | 2023-06-26 |
| BVF PARTNERS L P/IL | D-Return | 80,000 | $3.30 | 2023-06-26 |
| BVF PARTNERS L P/IL | D-Return | 80,000 | $4.49 | 2023-06-26 |